These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25412417)

  • 1. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds.
    Sasi NK; Tiwari K; Soon FF; Bonte D; Wang T; Melcher K; Xu HE; Weinreich M
    PLoS One; 2014; 9(11):e113300. PubMed ID: 25412417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
    Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C
    Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of XL413, a potent and selective CDC7 inhibitor.
    Koltun ES; Tsuhako AL; Brown DS; Aay N; Arcalas A; Chan V; Du H; Engst S; Ferguson K; Franzini M; Galan A; Holst CR; Huang P; Kane B; Kim MH; Li J; Markby D; Mohan M; Noson K; Plonowski A; Richards SJ; Robertson S; Shaw K; Stott G; Stout TJ; Young J; Yu P; Zaharia CA; Zhang W; Zhou P; Nuss JM; Xu W; Kearney PC
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3727-31. PubMed ID: 22560567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Replication Dynamics and Cellular Responses to ATP Competitive CDC7 Kinase Inhibitors.
    Rainey MD; Quachthithu H; Gaboriau D; Santocanale C
    ACS Chem Biol; 2017 Jul; 12(7):1893-1902. PubMed ID: 28560864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dbf4-Cdc7 (DDK) Inhibitor PHA-767491 Displays Potent Anti-Proliferative Effects via Crosstalk with the CDK2-RB-E2F Pathway.
    Pauzaite T; Tollitt J; Sopaci B; Caprani L; Iwanowytsch O; Thacker U; Hardy JG; Allinson SL; Copeland NA
    Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach.
    Cheng AN; Lo YK; Lin YS; Tang TK; Hsu CH; Hsu JT; Lee AY
    EBioMedicine; 2018 Oct; 36():241-251. PubMed ID: 30293817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDK Has a Primary Role in Processing Stalled Replication Forks to Initiate Downstream Checkpoint Signaling.
    Sasi NK; Coquel F; Lin YL; MacKeigan JP; Pasero P; Weinreich M
    Neoplasia; 2018 Oct; 20(10):985-995. PubMed ID: 30157471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XL413, a cell division cycle 7 kinase inhibitor enhanced the anti-fibrotic effect of pirfenidone on TGF-β1-stimulated C3H10T1/2 cells via Smad2/4.
    Jin SF; Ma HL; Liu ZL; Fu ST; Zhang CP; He Y
    Exp Cell Res; 2015 Dec; 339(2):289-99. PubMed ID: 26589264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DDK Promotes Tumor Chemoresistance and Survival via Multiple Pathways.
    Sasi NK; Bhutkar A; Lanning NJ; MacKeigan JP; Weinreich M
    Neoplasia; 2017 May; 19(5):439-450. PubMed ID: 28448802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
    Li W; Zhao XL; Shang SQ; Shen HQ; Chen X
    Curr Cancer Drug Targets; 2015; 15(3):196-204. PubMed ID: 25643258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
    Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
    Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cdc7 kinase - a new target for drug development.
    Swords R; Mahalingam D; O'Dwyer M; Santocanale C; Kelly K; Carew J; Giles F
    Eur J Cancer; 2010 Jan; 46(1):33-40. PubMed ID: 19815406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminopyrimidinone cdc7 kinase inhibitors.
    Woods KW; Lai C; Miyashiro JM; Tong Y; Florjancic AS; Han EK; Soni N; Shi Y; Lasko L; Leverson JD; Johnson EF; Shoemaker AR; Penning TD
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1940-3. PubMed ID: 22326396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors.
    Irie T; Asami T; Sawa A; Uno Y; Hanada M; Taniyama C; Funakoshi Y; Masai H; Sawa M
    Eur J Med Chem; 2017 Apr; 130():406-418. PubMed ID: 28279847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DDK dependent regulation of TOP2A at centromeres revealed by a chemical genetics approach.
    Wu KZ; Wang GN; Fitzgerald J; Quachthithu H; Rainey MD; Cattaneo A; Bachi A; Santocanale C
    Nucleic Acids Res; 2016 Oct; 44(18):8786-8798. PubMed ID: 27407105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structural basis of Cdc7-Dbf4 kinase dependent targeting and phosphorylation of the MCM2-7 double hexamer.
    Saleh A; Noguchi Y; Aramayo R; Ivanova ME; Stevens KM; Montoya A; Sunidhi S; Carranza NL; Skwark MJ; Speck C
    Nat Commun; 2022 May; 13(1):2915. PubMed ID: 35614055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stopping replication, at the beginning.
    Jackson PK
    Nat Chem Biol; 2008 Jun; 4(6):331-2. PubMed ID: 18488006
    [No Abstract]   [Full Text] [Related]  

  • 18. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
    Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
    Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
    Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
    Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.
    Huggett MT; Tudzarova S; Proctor I; Loddo M; Keane MG; Stoeber K; Williams GH; Pereira SP
    Oncotarget; 2016 Apr; 7(14):18495-507. PubMed ID: 26921250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.